Urothelial Carcinoma Treatment Market Research Report ‚Äď Forecast to 2030

Urothelial Carcinoma Treatment Market Research Report Information By Types (Non-Invasive & Invasive Urothelial Carcinoma), by Treatment (Immunotherapy, Radiotherapy, Chemotherapy), by End-User (Hospital Pharmacy, Retail Pharmacy, Others) ‚Äď Forecast Till 2030

ID: MRFR/Pharma/4983-HCR | 100 Pages | Author: Rahul Gotadki | October 2023         

Urothelial Carcinoma Treatment Market Speak to Analyst Request a Free Sample

Urothelial Carcinoma Treatment Market Scenario:


The Urothelial Carcinoma Treatment Market is anticipated to reach USD 3.2 Billion by 2030 at 19.10% CAGR during the forecast period 2022-2030.

Urothelial carcinoma is also called as transitional cell carcinoma which is a cancerous tumor of the bladder that can spread to other parts of the body. These are also called as malignant tumors. This tumor can start at any part of the urinary tract. People with bladder cancer may also have similar cancer in other parts of the urinary tract. Hence the market is expected to grow due to increasing prevalence of bladder cancer. Increasing investment in R&D activities to come up with new cancer treatment is also boosting the market for urothelial carcinoma treatment. As various awareness programs are carried out by government and non-government organizations regarding bladder cancer, it is expected to boost the market during the forecast period.  

Various factors that can hamper the growth of the market are the presence of the generic drug in the market and the high cost of R&D investment for the development of a new drug for treatment.


Urothelial carcinoma is when the bladder lining's urothelial cells alter and grow abnormally, eventually forming a mass known as a tumor. The rise of the market during the projected period is supported by the rising occurrence of bladder cancer worldwide. The most typical kind of bladder cancer is this one. Tumors in the ureter, urethra, and renal pelvis are common in people with bladder cancer. This tumor may have its beginnings anywhere along the urinary tract. Similar tumors in other parts of the urinary tract can develop in bladder cancer patients. Consequently, the market is projected to grow due to the increased prevalence of bladder cancer. Increasing R&D spending to develop new technologies for cancer treatment is also boosting the market for urothelial carcinoma treatment.


The market for drugs to treat urothelial cancer may expand quickly as people become more aware of bladder disorders and treatment options, as healthcare costs rise and the impact of bladder cancer increases. Additionally, the rising prevalence of bladder cancer worldwide supports the market's rise over the projected period. Depending on the goal of their use, chemotherapy medicines may be used singly or in combination. The most popular type of treatment used to halt or delay the proliferation of urothelial carcinoma cells is chemotherapy. It operates across the entire body to eliminate and prevent the spread of cancer cells to organs other than the original tumor. The segment is anticipated since chemotherapy is regarded as the first-line treatment for urothelial carcinoma.


When bladder tumors progress to deeper bladder layers and become challenging to treat, a problem is created. Blood in the urine, suffering, irritation in the bladder, changes in urination patterns, edema, sweating during the night, weight loss, and fever are among the common signs of urothelial cancer. The standard course of treatment for urothelial cancer is chemotherapy. Recent market approvals from significant companies present numerous prospects for industry expansion. For instance, better medicines that top drug regulatory organizations have approved will likely benefit the urothelial cancer medications market. The availability of generic medications on the market and the expensive nature of investing in research and development to create a new product are two issues that may impede the industry's growth. The high cost of treatment options restricts market expansion. The development of the market will probably be hindered by the high R&D costs resulting from producing urothelial cancer medications and the growing use of generic medications.



 

Urothelial Carcinoma Treatment Market Segmentation

 

The global urothelial carcinoma treatment market has been segmented on the basis of types, treatment, and end-users. Based on type the global urothelial carcinoma treatment is segmented into non-invasive and invasive urothelial carcinoma treatment. On basis of treatment, the market is segmented into immunotherapy, radiotherapy, and chemotherapy. Based on end-user the urothelial carcinoma market is segmented into hospital pharmacy, retail pharmacy, and others.

 

Urothelial Carcinoma Treatment Market Key players


  • GlaxoSmithKline plc

  • Genentech, Inc

  • Novartis AG

  • Dendreon

  • Merck KGaA

  • Eisai Co

  • Sanofi S.A

  • Bristol-Myers Squibb


News:


According to a study published in The Oncologist, first-line cisplatin-based chemotherapy offers those suffering from metastatic urothelial carcinoma the longest overall survival (OS) compared to other treatments. In this real-world trial, chemotherapy based on cisplatin had a median OS longer than chemotherapy based on carboplatin, immune checkpoint inhibitor (ICI) monotherapy, or nonplatinum therapy (apart from ICIs). ICI monotherapy had the highest total cost of care, while cisplatin-based chemotherapy also had the highest level of resource consumption in the healthcare system.



Regional Market Summary  

Global Urothelial Carcinoma Treatment Market Share (%), by Region, 2017


Urothelial Carcinoma Treatment Market Share


Source: Centers for Disease Control and Prevention (CDC)


On a regional basis, the market is segmented into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.


Americas is likely to dominate the urothelial carcinoma treatment market owing to the increasing prevalence of bladder cancer, increasing investment in research and development of new bladder cancer treatment. According to the American cancer society report, about 79030 cases of bladder cancer was reported in 2017 in the US.


Europe is the second largest market for the urothelial carcinoma treatment followed by Asia-Pacific. Due to growing awareness regarding early diagnosis of bladder cancer and developed healthcare infrastructure with increasing prevalence of urothelial cancer. Asia-Pacific shows the fastest growth in the market due to the low cost of R&D. India and China are expected to be the fastest growing market for bladder cancer treatment.


The Middle East and Africa has the lowest market for urothelial carcinoma treatment due to poor medical facilities and lack of technology.


Global Urothelial Carcinoma Treatment Market, by Type



  • Non-invasive urothelial carcinoma treatment

  • Invasive urothelial carcinoma treatment


Global Urothelial Carcinoma Treatment Market, by Treatment



  • Immunotherapy

  • Radiotherapy

  • Chemotherapy


Global Urothelial Carcinoma Treatment Market, by End-User



  • Hospital pharmacy

  • Retail pharmacy

  • Others


Global Urothelial Carcinoma Treatment Market, by Region


Americas

  • North America

  • US

  • Canada

  • South America


Europe

  • Western Europe



  • Germany

  • France

  • Italy

  • Spain

  • UK

  • Rest of Western Europe

  • Eastern Europe


Asia-Pacific

  • Japan

  • China

  • India

  • Australia

  • Republic of Korea

  • Rest of Asia-Pacific


Middle East & Africa

  • Middle East

  • Africa


Intended Audience



  • Hospitals and clinics

  • Laboratories and associations



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 3.2 Billion
  CAGR   2022-2030: 19.10%
  Base Year   2021
  Forecast Period   2030
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Types, Treatment, And End-Users
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   GlaxoSmithKline plc, Genentech, Inc., Novartis AG, Dendreon, Merck KGaA, Eisai Co., Sanofi S.A., Bristol-Myers Squibb
  Key Market Opportunities   Investment in R&D activities to come up with new cancer treatment
  Key Market Drivers   Growing prevalence of cancer


Frequently Asked Questions (FAQ) :

Urothelial Carcinoma, also known as transitional cell carcinoma, is a cancer of the urinary bladder that can spread to other parts of the body.

Urothelial Carcinoma is expected to exhibit a strong 19.10% CAGR over the forecast period from 2022 to 2030.

Growing prevalence of cancer is the major driver for the market.

Americas hold the largest share in the global Urothelial Carcinoma Market.

Leading players in the Urothelial Carcinoma Market include Sanofi, Genentech, and Novartis, among others.

Key Questions Answered

  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players‚Äô financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Request Free Sample

Why Choose Market Research Future?

  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.
Speak to Analyst
Leading companies partner with us for data-driven Insights.
Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo Client logo

Kindly complete the form below to receive a free sample of this Report

Please fill in Business Email for Quick Response
Invalid